Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...
Business Insider on MSN6d
It's about to get a lot harder to buy knock-off OzempicLots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...
Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...
Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...
Looking for a reliable way to lose weight?? Meet Mounjaro UAE, the latest injectable medication that’s making waves among ...
The yearlong downtrend in obesity drug supplier Novo Nordisk (NVO) is potentially over. Last Friday, Jan. 25, NVO stock gained 8.47% to close at $87.97. The company posted the results of its obesity ...
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback